Last reviewed · How we verify

NCT04981821: GO-EXCAP2

A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms

Recruiting now NA Last updated 3 April 2026
What this trial tests

NA trial testing GO-EXCAP Mobile App in Cancer in 170 participants. Currently enrolling.

Timeline
3 January 2022
Primary endpoint
30 June 2026
31 December 2026

Quick facts

Lead sponsorUniversity of Rochester
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment170
Start date3 January 2022
Primary completion30 June 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Rochester

Who can join

60 and older, any sex, with Cancer or Myeloid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2 randomized controlled trial (RCT) to assess the preliminary efficacy of the a mobile health exercise intervention (GO-EXCAP) versus a chemotherapy education control in 100 older patients with MN receiving outpatient chemotherapy on physical function and patient-reported outcomes (fatigue, mood, and quality of life). We will also explore the effect of the intervention on TNFα and related cytokine gene promoter methylation and their gene and protein expression.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms.
    Loh KP, Sanapala C, Watson EE, Jensen-Battaglia M, et al · · 2022 · cited 28× · PMID 35320340 · DOI 10.1182/bloodadvances.2022007056
  2. Exercise and epigenetic ages in older adults with myeloid malignancies.
    Loh KP, Sanapala C, Jensen-Battaglia M, Rana A, et al · · 2023 · cited 13× · PMID 37254221 · DOI 10.1186/s40001-023-01145-z
  3. Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2).
    Loh KP, Sanapala C, Janelsins M, Klepin HD, et al · · 2022 · cited 6× · PMID 34949540 · DOI 10.1016/j.jgo.2021.12.011
  4. Exercise and inflammatory cytokine regulation among older adults with myeloid malignancies.
    Loh KP, Wang Y, Sanapala C, Gilmore N, et al · · 2024 · cited 3× · PMID 38266886 · DOI 10.1016/j.exger.2024.112364
  5. Changes in muscle performance among older adults with myeloid malignancies engaging in a mobile health (mHealth) exercise intervention: a single arm pilot study.
    Jensen-Battaglia M, Lin PJ, Sanapala C, Watson EE, et al · · 2025 · cited 2× · PMID 39789445 · DOI 10.1186/s12877-024-05668-w
  6. In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies.
    Sanapala C, Jensen-Battaglia M, Watson EE, Konatham S, et al · · 2023 · cited 1× · PMID 36790922 · DOI 10.1182/bloodadvances.2022009396
  7. Gait Changes After a Mobile Health Exercise Intervention in Older Adults With Myeloid Neoplasms: Single-Arm Pilot Trial.
    Wang Y, Jensen-Battaglia M, Lin PJ, Kleckner I, et al · · 2026 · PMID 42054674 · DOI 10.2196/80909

Verify or expand the search:

Other trials of GO-EXCAP Mobile App

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other University of Rochester trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04981821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing